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Objective: Comprehensive clinical characterization of congenital titinopathy to facilitate diagnosis and management
of this important emerging disorder.
Methods: Using massively parallel sequencing we identified 30 patients from 27 families with 2 pathogenic nonsense,
frameshift and/or splice site TTN mutations in trans. We then undertook a detailed analysis of the clinical, histopathological and imaging features of these patients.
Results: All patients had prenatal or early onset hypotonia and/or congenital contractures. None had ophthalmoplegia. Scoliosis and respiratory insufficiency typically developed early and progressed rapidly, whereas limb weakness
was often slowly progressive, and usually did not prevent independent walking. Cardiac involvement was present in
46% of patients. Relatives of 2 patients had dilated cardiomyopathy. Creatine kinase levels were normal to moderately elevated. Increased fiber size variation, internalized nuclei and cores were common histopathological abnormalities. Cap-like regions, whorled or ring fibers, and mitochondrial accumulations were also observed. Muscle magnetic
resonance imaging showed gluteal, hamstring and calf muscle involvement. Western blot analysis showed a
near-normal sized titin protein in all samples. The presence of 2 mutations predicted to impact both N2BA and N2B
cardiac isoforms appeared to be associated with greatest risk of cardiac involvement. One-third of patients had 1
mutation predicted to impact exons present in fetal skeletal muscle, but not included within the mature skeletal muscle isoform transcript. This strongly suggests developmental isoforms are involved in the pathogenesis of this congenital/early onset disorder.
Interpretation: This detailed clinical reference dataset will greatly facilitate diagnostic confirmation and management
of patients, and has provided important insights into disease pathogenesis.
ANN NEUROL 2018;83:1105–1124

T

TN (Online Mendelian Inheritance in Man database
[OMIM] #188840) includes the most exons (364)
and has the longest coding sequence (>100kb) of any
human gene. It encodes titin, the largest protein in
nature (maximum size 5 4,200kDa).1 In striated (cardiac

and skeletal) muscle, each titin molecule pairs with a second antiparallel titin molecule to span the full length of
the sarcomere like two “springs in series,”2 forming a
continuous elastic myofilament. These myofilaments provide a scaffold for sarcomere assembly during muscle
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development,3–5 generate passive tension, maintain sarcomeric structural integrity, and serve as key mechanosensing and signaling hubs (reviewed in Gautel and
Djinovic-Carugo6).
Titin comprises an amino-terminal Z-disc region,
middle I- and A-band regions, and a carboxy-terminal
M-band region (Fig 1). Differential splicing of titin (particularly PEVK exons) yields alternative isoforms with
different lengths and elastic properties. In humans, there
is one characterized mature soleus-derived skeletal muscle
isoform, N2A.1,7 There are also multiple mature cardiac
isoforms (http://cardiodb.org/titin/titin_transcripts.php).8
Developmental skeletal and cardiac muscle isoforms have
also been described at the protein and individual exon
expression level.9,10
Autosomal dominant TTN mutations cause 2 adult
onset skeletal muscle disorders: (1) tibial muscular dystrophy (TMD; OMIM #600334)11 and (2) hereditary

myopathy with early respiratory failure (HMERF; OMIM
#603689).12,13 All reported TMD mutations are within
the final 6 (M-band) exons. HMERF is caused by missense mutations within exon 344. Heterozygous truncating
TTN mutations are the most common genetic cause of
dilated cardiomyopathy (DCM; OMIM #604145).14–16
A specific Finnish founder mutation that causes
TMD in heterozygous individuals causes limb girdle
muscular dystrophy in homozygous individuals (OMIM
#608807).11,17 Various homozygous and compound heterozygous TTN mutations have also been reported in
patients with childhood, adolescent, and adult onset
recessive distal titinopathy,18,19 and childhood-juvenile
onset Emery-Dreifuss–like titinopathy.20
To date, 16 patients from 12 families with a recessive prenatal or infant onset form of titinopathy have
been reported. Previous cases were described as early onset
myopathy with fatal cardiomyopathy,21 centronuclear
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FIGURE 1: Schematic representation of titin isoforms and location of patient mutations. (A) Size (relative to number of amino
acids) of the 4 main titin regions encoded by the inferred complete metatranscript (Refseq transcript NM_001267550.1), the
single characterized skeletal muscle isoform N2A (Refseq transcript NM_133378.4), the principal cardiac long isoform N2BA
(NM_001256850.1) and the principle cardiac short isoform N2B (NM_003319.4). The Z-disc region of titin (green) interacts with
a-actinin, telethonin, and other Z-disc–related proteins. The I-band region (blue) contains multiple tandem immunoglobulin-like
domains and the “PEVK” domain (yellow), which is rich in proline (P), glutamic acid (E), valine (V), and lysine (K). The PEVK domain
unravels when stretched, giving titin its elastic properties. The A-band region (red) contains multiple myosin and C-protein binding
sites, and alternating fibronectin type III and immunoglobulin repeats that form a shape that complements myosin. The M-band
region (purple) is encoded by the last 6 exons [M-band exon (Mex) exons 1–6 (exons 359–364)] and contains a kinase domain,
immunoglobulin domains, and binding sequences for calpain 3, obscurin, MURF-1, and numerous other proteins, along with
additional unique sequences. The gray regions shown within N2A, N2BA, and N2B are those included in the metatranscript
but not present within the relevant isoform. Thick black lines within the gray regions represent smaller subregions that are
retained by the isoform, but are not large enough to show up as a colored segment. (B) Location of each of the mutations
identified in our clinical analysis cohort (Families 1–27) mapped to the inferred complete metatranscript. Splice site mutations are shown above the transcript image. Frameshift and nonsense mutations are shown below the transcript. Supplementary Table 1 shows which mutations are included in N2A, N2BA and/or N2B. (Schematic images were created using
Illustrator for Biological Sequences.)

myopathy,22 core myopathy with heart disease,23 and
arthrogryposis multiplex congenita with myopathy.24 We
suggest the term “congenital titinopathy” be adopted for
this disorder.25 Previously reported patients had a range of
different causative mutations, including more difficult-tointerpret missense changes. Clinical features included
neck, axial, and limb weakness, joint contractures, spinal
and chest wall deformities, early onset respiratory insufficiency, mild facial weakness and ptosis. Congenital cardiac
anomalies and/or childhood or adolescent onset DCM
were common (10/16 patients). Creatine kinase (CK) levels were normal to moderately elevated. Muscle biopsies
showed increased internalized and central nuclei, minicores and/or dystrophic lesions.
To facilitate diagnostic assessments and to better
understand the natural history of congenital titinopathy,
we analyzed the clinical, muscle pathology and imaging
findings in a large international cohort with recessively
1108

inherited nonsense, frameshift and/or splice site TTN
mutations; that is, the most pathogenically-convincing
subset of mutations. Patients with difficult-to-interpret
missense variants were excluded, to gain the clearest possible clinical picture of this disorder.

Subjects and Methods
Ethical Approval and Consent
The project was approved by the Human Research Ethics Committee of the Sydney Children’s Hospitals Network and by
other researchers’ relevant institutional review boards. Informed
consent for research participation and use of clinical photographs, including 3 non-obscured facial photographs, was
obtained from patients/parents/legal guardians.

Recruitment
Patients were ascertained from neurology clinics. The study
included published and unpublished clinical data from Families
13 to 16, reported previously as 314-1, 979-1, 1044-1, and
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1093-1 respectively.22 The Family 10 proband has also been
described.26

Mutation Detection, Confirmation, and
Annotation
The type of massively parallel sequencing (MPS) technology used
to identify each causative mutation (panel, whole exome sequencing, whole genome sequencing) is shown in Supplementary Table
1. Bioinformatics analysis pipelines focused on rare compound heterozygous or homozygous variants within known neuromuscular
disease genes that were likely to be pathogenic. Variants in genes
associated with cardiac abnormalities in the absence of neuromuscular pathology were not systematically analyzed in most cases.
Each mutation was Sanger-confirmed and reported
according to Human Genome Variation Society recommendations (http://varnomen.hgvs.org/) using the inferred complete
TTN metatranscript as reference (NM_001267550.1;
LRG391_t1). Exons were numbered 1 to 364 according to the
LRG schema. Family members were Sanger sequenced to confirm segregation and carrier status.
The Leiden Muscular Dystrophy (http://www.dmd.nl/),
ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), and Cardiodb
mutation databases (http://cardiodb.org/titin/) were interrogated
to identify previously reported mutations. The Exome Aggregation Consortium (ExAC) database (http://exac.broadinstitute.
org/) was used to determine the frequency of each mutation in
R Visual (Interactive Biosoftthe general population. AlamutV
ware, North Seattle, WA) was used to predict the impact of
splice site mutations.

Clinical Features Analysis
The clinical analysis cohort included patients with 2 Sangerconfirmed nonsense, frameshift and/or splice site mutations
shown to be in trans by segregation studies. The single exception was the Family 7 proband, who had a homozygous mutation and history of parental consanguinity; however, parental
DNA was unavailable. The data from clinical analysis cohort
members (henceforth referred to as patients) were collected
from primary medical records and managing clinicians, tabulated, and the percentage of patients with each feature calculated. The denominator for each calculation (shown in Table 1
and Supplementary Table 2) was the number of patients for
whom data were available for that feature, rather than total
cases. As patients “unknown” for any feature are more likely to
have been negative than positive for that feature, this approach
may have resulted in a small overestimation of prevalence.
Four additional segregation-inconclusive families (Families 28–31) were studied, but not included in the clinical analysis cohort.

Cardiac Isoform Analysis
The Cardiodb database (http://cardiodb.org/titin) was interrogated to determine which mutations were predicted to alter the
2 most abundant adult cardiac isoforms, N2BA and N2B. Families were stratified according to the cardiac status of affected
members (“Yes” 5 cardiac involvement in at least 1 member),
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and whether each had (1) 2 mutations predicted to alter both
N2BA and N2B or (2) other combinations of mutations. Significance was determined using Fisher’s Exact Test.

Western Blot Analysis
Western blot analysis of 5 patient muscle samples (Families 4,
5, 13, 15 and 16) and 2 segregation-inconclusive cases (Families
28 and 29) was undertaken. Biopsy protein extracts were electrophoresed on 0.8% agarose gels and transferred to polyvinylidene difluoride membranes using a semidry transfer system
(Bio-Rad Laboratories, Hercules, CA). Affinity-purified rabbit
polyclonal antibodies specific for the titin N-terminus (a-Z1Z2;
Myomedix, Neckargem€und, Germany) and C-terminus (aM8M9; Myomedix) were used (1:2,500 dilution). Fluorescent
secondary antibodies with infrared excitation (LI-COR Biosciences, Lincoln, NE) were used (1:20,000 dilution). Blots were
scanned with the Odyssey Infrared Imaging System (LI-COR
Biosciences).

Splicing, cDNA and RNAseq Analysis
Direct analysis of the impact of each mutation was beyond the
scope of this study; however, an in vitro hybrid minigene splicing assay was previously used to evaluate the transcriptional
consequences of 2 splice site changes.22
The impact of an extended splice site deletion (Family 6:
exon 317: c.6676914_6676917del) was evaluated using cDNA
analysis. cDNA was synthesized from 1 mg of total skeletal muscle
RNA using the SuperScriptTM III First-Strand Synthesis System
(Invitrogen, Carlsbad, CA) for reverse transcription polymerase
chain reaction (PCR), according to the manufacturer’s protocol
(90 minute cDNA synthesis). RNA was primed with oligo(dt) or
random primers. One microliter of the resulting cDNA was used
in PCR reactions. The primers were: forward 50 AACCGCCTCTTGAAGATGGA-30 (NG_011618.3 exon 315)
and reverse 50 - TGGAGCACTCAGTTGTCACT-30 (exon 319).

Results
Demographic Information
The study cohort consisted of 30 patients from 27 families. The demographic features are described in Supplementary Table 2. Four patients were deceased at
ascertainment, and 1 died during the study. Cause of
death was (1) early respiratory failure (2 patients: Family
6 proband on day 1 [38 weeks gestation] and Family 18
proband at 3 months of age); (2) sudden death at age
8 years in the context of mild–moderate DCM, with
arrhythmia suspected (Family 7 proband); (3) pneumonia
at age 13 years (Family 10 proband); and (4) bowel cancer during early 30s (Sibling 2/Family 1). Of the 25 surviving patients, age at ascertainment ranged from 9
months to 34 years.
As only 5 patients were  18 years old (see Supplementary Table 2), it was not possible to comprehensively
characterize the features or natural history of this disorder
1109
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TABLE 1. Summary of common and clinically significant features
More detailed information regarding overall findings is provided in Supplementary Table 2.
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1

Denominator is number of cohort members with data provided for that feature/item.
Fraction converted to percentage of cohort members with each feature.
3
Reduced movements from first onset of movements in pregnancy in at least 1 case; no data were available regarding fetal movements for 1
patient.
4
Talipes noted as early as 15 weeks gestation in 1 case.
5
A significant subset of congenital limb contractures were not noted on prenatal ultrasound.
6
Both congenital scoliosis cases were brothers from the same family (Family 1).
7
Submucous cleft in 2 of 3 cases; cleft in context of Pierre Robin sequence in 3rd case.
8
Only one cohort member lost the ability to walk independently once he had achieved the ability to walk (lost at age 7 years) as a result of progressive contractures and foot deformities (“walk independently” is defined as able to walk without any assistive devices, for example, calipers).
9
At least 1 cohort member had a positive Gowers’ maneuver in early childhood but had lost this by age 7 years.
10
“Slow” is defined as still ambulant or likely to be still ambulant after 20 years of age.
11
“Moderate” is defined as loss or likely loss of ambulation between 10 and 20 years of age.
12
“Rapid” is defined as loss or likely loss of ambulation before 10 years of age.
13
Degree of muscle weakness is rated according to weakest muscle group for each cohort member. For example, if at least 1 muscle group is rated
as “severe,” overall rating is “severe.”
14
Deep tendon reflexes were normal in a single cohort member with congenital contractures (camptodactyly and talipes) but no history of limb
weakness (Family 19 proband).
15
Ptosis was typically mild, occasionally unilateral, and congenital in at least 1 cohort member.
16
Data regarding these features were not specifically requested during the formal data collection process but were reported spontaneously in descriptive data for >1 cohort member and were therefore noteworthy. As dataset is incomplete, a denominator and percentage are not provided.
17
In a small subset of additional cases, rotational deformity of the spine had resulted in prominence of one side of the chest wall. These were
counted as “no/absent” for chest wall deformity.
18
“Respiratory insufficiency” is defined as reduced force vital capacity and/or oxygen requirement and/or ventilation requirement.
19
Only 2 cohort members with respiratory insufficiency had no scoliosis or chest wall deformity. One was a 9-month-old infant on full-time ventilation who may yet develop truncal deformities. The other was a 32-year-old male who was lost to follow-up from age 17 years.
20
Diaphragmatic/paradoxical breathing pattern data were available for only 12 cohort members (incomplete data ascertainment). This feature could
not be assessed in severely affected infants requiring full-time ventilatory support.
21
Many cohort members had not been screened for osteopenia at the time of ascertainment.
22
Mild intellectual disability was reported in 2 brothers from Family 26; 1 also had attention-deficit/hyperactivity disorder.
23
One cohort member had undergone 4 separate surgical procedures, and several had undergone 2 procedures.
24
Upper limb electromyography was felt to be neuropathic in 1 subject who died at 3 months of age. The lower limb findings in this infant were normal.
25
Additional descriptive data regarding pattern of muscle involvement in lower limb MRI are provided in the text.
CK 5 creatine kinase; CMAP 5 compound motor action potential; D 5 distal; fx 5 features; inv 5 involvement; LL 5 lower limbs; MRC 5 Medical
Research Council scale for muscle strength; MRI 5 magnetic resonance imaging; NOS 5 not otherwise specified; P 5 proximal; PEG 5 percutaneous gastrostomy tube; UL 5 upper limbs.
2

during adulthood.
represented.

Younger

patients

were

well

Mutations
The 45 different mutations identified in clinical analysis
cohort members (from Families 1-27) are shown in Figure
1 and detailed in Supplementary Table 1. Thirty-three
mutations were novel. Fifteen mutations were nonsense
and 14 were frameshift. Thirteen of the 16 splice site
mutations were essential/canonical (altering the first or last
2 bases of an intron). Two were exonic (altering the last
base of an exon). One was a small extended splice site
deletion (Family 6: c.6676914_6676917del). All mutations were rare (frequency < 0.1% in ExAC).
Four mutations from 8 unrelated families (Families
20–27) were within the inferred complete TTN metatranscript (NM_001267550.1) but not within exons that
encode the N2A mature skeletal muscle isoform
June 2018

(NM_133378.4) or the multiple mature cardiac isoforms. In support of the pathogenicity of these
“metatranscript-only” mutations, the exon 163 nonsense
mutation (p.Glu11932*) was a recurrent mutation present in 5 unrelated cohort families (Families 20, 21, 23,
24, and 25) and 1 segregation-inconclusive family (Family 31).
Two additional mutations were also recurrent mutations present in 2 unrelated cohort families (p.Val10952Leu exonic splice mutation present in Families 4 and 13,
and c.1549611G>A present in Families 1 and 14; see
Supplementary Table 1).
Family History
Five probands had 1 affected sibling. Clinical data from
3 of these siblings (from Families 1, 20, and 26) were
available for inclusion in the analysis (see Supplementary
Table 1). There was no history of weakness or other
1111
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neuromuscular abnormalities among the first-degree relatives of cohort patients.
Only 19 of the carrier-confirmed parents from 11
of 27 clinical analysis cohort families and an even smaller
subset of extended family members had undergone cardiac screening (shown in Supplementary Table 1). Of
specific note is that two families (Families 9 and 13) had
first- and/or second-degree relatives with DCM. All 3
Family 13 maternal members with DCM were heterozygous carriers. The maternally inherited mutation from
this family was novel. In a third family (Family 12), a
sibling pregnancy had been terminated due to congenital
heart disease (fetal mutation status unknown). There was
also a strong family history of cardiomyopathy (both
parents and a paternal uncle) in 1 segregationinconclusive family (Family 29).
The 77-year-old Family 1 father and 2 older paternal mutation-carrier relatives from Family 13 had additional cardiac abnormalities of unknown significance
(atrial fibrillation in all 3 and mitral valve changes in 2
of 3; details in Supplementary Table 1).
Five parents (from Families 3, 4, 5, 13, and 25)
carried a mutation previously reported in the DCM literature (DCM-mutation) but had normal cardiac findings
(2 parents) or had not yet had cardiac screening (3
parents; additional details in Supplementary Table 1).
The Family 5 maternal carrier of a previously reported
congenital titinopathy-cardiac-mutation (p.Gln35278*)23
had no cardiac involvement on recent screening.
Clinical Features
Common and significant clinical features, and the prevalence of each feature, are summarized in Table 1, with
more detailed clinical information provided in Supplementary Table 2. Selected features are illustrated in Figure 2.
PREGNANCY/CONGENITAL FEATURES. Almost 60%

of patients had reduced fetal movements. Features of the
disorder developed in utero or were present at birth in all
but four cases (exceptions: symptoms/signs first noted at
3 months (two patients), 8 and 14 months). One patient
(Family 19 proband) had congenital finger contractures
and unilateral talipes, but no apparent weakness at birth
and remains strong (current age 5 21 years).
Congenital limb contractures were common (61%),
and often distal (involved joint[s] are shown in Supplementary Table 2). Twelve patients (43%) had congenital
contractures involving  2 areas consistent with the clinical diagnosis of arthrogryposis multiplex congenita
(AMC). Congenital scoliosis and fractures were each present in 2 patients (congenital scoliosis was present in
1112

both Family 1 siblings; congenital fractures were present
in Family 6 proband and Sibling 1/Family 26).
Neonatal feeding and respiratory difficulties were
common (63% and 41%). Most patients required only
a brief period of respiratory support after birth. Three
patients (Family 12, 17, and 18 probands) had
required nocturnal or all-day ventilation from the neonatal period onward.
LIMB WEAKNESS, CONTRACTURES, MUSCLE BULK
AND MOTOR DEVELOPMENT. In most cases, limb

weakness was predominantly proximal and symmetrical,
and affected both upper and lower limbs. Severity was
typically mild to moderate (Medical Research Council
[MRC] 3–4/5), but sometimes severe (MRC 2/5 or less).
Generalized muscle wasting was common (75%). Calf
hypertrophy was rare (Family 13 proband only).
Acquired limb contractures were frequent (67%), affected
both proximal and distal joints, and were often multiple
(see Supplementary Table 2).
A total of 19 of 30 patients could, or had previously been able to walk. Three (11%) were younger than
5 years and might still walk. Nine patients could walk
fast or run, and 4 could jump. Rate of ambulatory loss
was often slow (defined as “still ambulant or predicted to
be still ambulant after 20 years of age”; 9/19 patients),
and 4 of 19 patients were still gaining rather than losing
walking ability (see Supplementary Table 2). Only 1
patient had lost the ability to walk independently (without aids) once achieved (Family 2 proband; unable to
walk from age 7 years). Another initially walked with calipers but became wheelchair dependent at age 4 years
(Family 5 proband). Three were experiencing increasing
walking difficulties due to progressive weakness, pain,
contractures, foot deformities, and/or fatigue (Family 7,
8, and 15 probands).
AXIAL FEATURES AND RESPIRATORY INSUFFICIENCY.

Neck flexion weakness was present in all but 1 of
the 21 patients for whom data were available. Neck
extension weakness was also common (83%). Three
patients had a striking “dropped head” phenotype (Sibling1/Family 1, Sibling 1/Family 26, and Family 2
proband).27
Many patients (63%) had objective evidence of
respiratory impairment, and 44% required nocturnal or
full-time ventilation. Scoliosis was present in 57% of
patients and was typically early-onset, rapidly progressive,
and had required (or was likely to require) intervention.
Chest wall deformities and scapular winging were present
in 43% and 45% of patients respectively. Scoliosis, chest
wall deformities, and respiratory insufficiency were often
concurrent. Spinal rigidity, kyphosis, and lumbar
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hyperlordosis were sometimes present (6, 3, and 6 cases
respectively).
CARDIAC ABNORMALITIES. Thirteen patients (46%)
had congenital and/or early onset cardiac pathology (see
Supplementary Tables 1 and 2). Nine had congenital cardiac abnormalities. Five had early onset cardiac complications including dilated cardiomyopathy (onset at 18
months and 9 years), left ventricular dysfunction (onset
at 3 years and “during childhood”), or a dilated right
ventricle (autopsy finding at age 13 years). Some cardiac
abnormalities progressed rapidly and/or were associated
with life-threatening arrhythmias.
Two patients with structural cardiac abnormalities
(Family 4 and 25 probands) had 1 reported DCM-mutation15 in combination with 1 novel mutation (see Supplementary Table 1). The patient with the most severe
congenital anomaly (Family 5 proband: aortic coarctation) was the only patient to have 2 previously reported
cardiac mutations (a DCM-mutation14 and a congenital
titinopathy-cardiac-mutation23). The remaining 10
patients with cardiac involvement had no previously
reported cardiac mutations.
FACIAL FEATURES, FEEDING ABNORMALITIES AND
OTHER NOTABLE FINDINGS. No patient had oph-

thalmoplegia (based on data for 26/29 patients who survived beyond day 1 of life). High-arched palate and mild
to moderate facial weakness were common (73% and
70%). Ptosis was present in 33%, and was occasionally
congenital, asymmetrical or fluctuating. A submucous
cleft palate was present in 2 patients (Family 19 and 22
probands). A third patient had Pierre Robin sequence
(Family 5 proband). Growth abnormalities, torticollis,
facial asymmetry, and a range of dysmorphic features
were noted in more than one patient (see Supplementary
Table 2).
Several patients were reported to have a Noonanlike facial appearance, sometimes in combination with
other Noonan-associated features (low posterior hairline,
neck webbing, short stature); however, ascertainment of
these features was incomplete.
Sucking, chewing, and/or swallowing difficulties
affected 38% of patients, and 26% required supplemental tube or gastrostomy feeding.
Joint hypermobility was present in 73% of patients.
Only 2 siblings had a history of learning difficulties
(mild: Family 26). Four patients had documented osteopenia, 2 with pathological fractures. None had experienced malignant hyperthermia during exposure to
anesthetic agents.
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CK Levels and Electrophysiology Results
CK levels were typically normal but occasionally elevated
(400–2,3241 IU/L). Nerve conduction velocities were
normal. Electromyography was usually normal (50%) or
myopathic (40%).
Magnetic Resonance Imaging
Three of the 12 patients with magnetic resonance imaging (MRI) brain results had minor structural abnormalities of unknown significance (see Supplementary Table
2). Two severely affected infants had birth hypoxia or
birth trauma-related features, but normal cerebral
morphology.
Descriptions of pelvic and lower limb MRI findings
were available for 3 patients (at ages 3, 9, and 15 years),
with original images for 1 of the 3 (Family 26, 15 years; see
Fig 2L–N). All 3 cases showed paraspinal, gluteal, and
global hamstring atrophy. The adductors, sartorius, and gracilis were spared or hypertrophied. In the lower limb, the
gastrocnemius and soleus were variably involved. Muscle
MRI signs associated with clinically similar disorders, for
example SEPN1- and COL6-myopathies28–30 were absent.
Original images from a segregation-inconclusive
case at age 29 years (Family 31; see Fig 2O-Q) showed
severe involvement of the gluteal and anterior compartment muscles and all 3 components of the visible hamstring muscles, with clear adductor sparing and marked
calf atrophy. This case may represent a more severe and/
or more advanced case.
Muscle Pathology
One patient from each family had undergone at least 1
muscle biopsy (source of data, age, site, and findings are
listed in Table 2), with the single exception of Family
19. Examples of biopsy features are shown in Figure 3.
All muscle biopsies were abnormal. The histopathologic changes fell into 3 main patterns: (1) increased fiber
size variation (FSV; present in  1 biopsies from 89% of
families), (2) increased internalized nuclei (IN; 59%),
and (3) cores (48%), with additional structural abnormalities in some cases. Seven biopsies had FSV alone, 1
had IN alone, and 1 had only cores (multiminicores).
The remaining biopsies had a combination of 2 main
patterns with or without additional structural abnormalities (see Table 2, Fig 3M).
Where fiber type information was available, the
pattern was of type 1 fiber type disproportion (small predominant type 1 fibers and fiber size disproportion of
>12%; see Fig 3H). One biopsy (see Fig 3I; Family 2
proband) fulfilled histopathological criteria for congenital
fiber type disproportion.31
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A subset of biopsies with increased IN (present
in  3% of fibers) had nuclei in the geographical center of
the fiber (see Fig 3A,C). Seven biopsies had been given the
histopathological diagnosis of centronuclear myopathy
(CNM). When the IN were not centralized, and there was
significantly increased fibroadipose tissue, fiber splitting,

and/or additional architectural abnormalities, the biopsies
had typically been reported as “dystrophic” or “severely
myopathic” (see Fig 3L). Signs of regeneration and/or
degeneration were minimal or absent.
Multiminicores (see Fig 3D–F) were more common
than centrally placed cores (see Fig 3G). Centrally placed

FIGURE 2.
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cores typically had the appearance of larger, perhaps
merged minicores. Central cores extending down the
majority of the longitudinal fiber axis were not seen on
available electron micrograph images.
Rarer structural abnormalities seen (see Table 2)
included cap-like regions (see Fig 3J, K), ring, coiled,
and whorled fibers, and striking central and peripheral
mitochondrial accumulations. A subset of biopsies
showed variable fiber type grouping.
Additional features associated with MTM1-,
DNM2- and RYR1-centronuclear myopathy, such as central accumulation of oxidative stains, radial arrangement
of sarcomeres, or necklace fibers, were not observed.
Rimmed vacuoles (described in HMERF and TMD)
were absent.
Autopsy Findings
The main features of the 2 autopsied deceased patients
are shown in Table 3. Brain and spinal cord were normal
in both patients.
Subgroup Analysis Of Patients with Mutations
that are predicted to have no Impact on the
N2A Skeletal Muscle Isoform Transcript
We compared the clinical features of the 10 patients with
metatranscript-only mutations to those seen in the combined clinical analysis cohort (see Supplementary Table
3). Respiratory involvement appeared less common in
this subgroup; however, this subgroup was younger at
ascertainment (average age 5 9 years vs 12.5 years). Cardiac involvement was also rare (only mild pulmonary

stenosis in the Family 25 proband, who also had a
DCM-mutation). The 2 patients with mild intellectual
disability and 2 of the 3 patients with structural brain
abnormalities were in this subgroup. Internalized nuclei
were often present; however, no subgroup member had a
centronuclear myopathy biopsy picture. The remaining
clinical and histopathological features were similar.
Cardiac Isoform Analysis
As shown in Table 4, cohort families with 2 mutations
predicted to impact both N2BA and N2B cardiac
isoforms showed a trend toward an increased likelihood
of cardiac involvement (pFisher 5 0.087, odds ratio
[OR] 5 6.0, 95% confidence interval [CI] 5 0.78–78).
This achieved statistical significance with the inclusion of
5 previously published congenital titinopathy families
with 2 truncating mutations (from Carmignac et al,21
Chauveau et al,23 and Fernandez-Marmiesse et al24) in
the analysis (p 5 0.009, OR 5 11, 95% CI 5 1.6–130).
The pattern held with the addition of the 2 published
families with 1 truncating and 1 missense mutation
(from Chauveau et al23; p 5 0.002, OR 5 13, 95%
CI 5 2.0–150).
Western Blotting
All 7 muscle biopsies analyzed by western blot showed a
band corresponding to full-length or nearly full-length
titin skeletal muscle isoform; N2A (Fig 4). A full-length/
nearly full-length band was seen with the N-terminal
antibody in all 7 cases, and with the C-terminal antibody

FIGURE 2: Examples of common and clinically significant features. Lower limb magnetic resonance imaging (MRI) is also shown.
(A) Female Family 25 proband. The pregnancy for this infant was complicated by reduced fetal movements and prenatal ultrasound detection of limb contractures. The image shows typical “frog leg” positioning due to marked congenital hypotonia and
weakness. Note also the nasogastric feeding tube and reduced palmar creases (inset). This infant also had mild pulmonary stenosis and needed intubation and ventilation for a short period following delivery. (B, C) The older of the 2 affected brothers
(Sibling 1) from Family 1 at age 34 years. Both brothers had congenital scoliosis, which progressed during childhood. Spinal
surgery was not possible in the pictured brother due to concurrent development of severe respiratory insufficiency. His respiratory deficit was diagnosed at age 13 years following an out of hospital respiratory arrest, and he has since relied on nocturnal
ventilation via a tracheostomy tube. This patient has slowly progressive mild to moderate limb weakness but remains ambulant
despite significant axial involvement. He also has left ventricular cardiac dysfunction. In addition, these images demonstrate
bilateral non-congenital elbow contractures and marked generalized muscle hypotrophy. (D) Family 24 female proband who
was born following a pregnancy complicated by reduced fetal movements and breech presentation. She was significantly hypotonic at birth and had congenital bilateral wrist contractures and fixed foot deformities. (E, F) Ptosis and facial weakness in the
younger sibling (Sibling 2) from Family 26 during early childhood (E) and at age 12 years (F). (G, H) The same child as shown in
(A) at age 2 years with a pectus excavatum chest wall deformity (G) and scapular winging (H). (I) Distal joint hypermobility in
Sibling 1 from Family 1. (J, K) Reduced range of neck movement in Sibling 1 from Family 26. (L–N) Lower limb MRI result for
Sibling 1 from Family 26 at age 15 years. This shows fatty infiltration of the gluteal muscles (L), severe fatty replacement of
both visible hamstring muscles (complete fatty replacement of semitendinosus and incomplete but marked replacement of
biceps femoris; M), relative sparing of the adductor compartment, and mild involvement of the calf and peroneal muscles (N).
(O–Q) Lower limb MRI result for the Family 31 proband at age 29 years. This is one of the 4 segregation-inconclusive cases
described in this paper, but not included within the clinical analysis cohort. The features in this individual’s lower limb MRI may
represent the more severe end of the spectrum of muscle involvement associated with this disorder. The images show severe
fatty replacement of the quadriceps and hamstrings, sparing of the adductors (also seen in the first MRI case), and severe
replacement of both calves and the right peroneus, with mild fatty marbling in the anterior and lateral compartment on the
left. Consent was obtained from patients/parents/legal guardians for use of the clinical photographs shown in this figure,
including the non-obscured facial photographs shown in D–F.
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TABLE 2. Summary of skeletal muscle histopathology and ultrastructural (EM) features
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This table summarizes the main histopathological patterns seen in clinical analysis cohort members and in segregation-inconclusive cases. Families
1–18 had segregation-confirmed congenital titinopathy. No biopsy was undertaken in the Family 19 proband. Families 20–27 have segregationconfirmed congenital titinopathy with 1 metatranscript-only mutation that impacts an exon not included within the reference mature skeletal muscle isoform, N2A. Families 28–31 have a range of congenital titinopathy-like clinical features (as shown in Supplementary Table 3), but inconclusive segregation results due to absence of carrier status data from one parent (Families 28 and 29) or absence of either mutation in one parent
(Families 30 and 31). FSV, IN, cores, and “other” structural features are defined in “Results: Muscle Pathology.” Cases with 1 metatranscript-only
mutation had similar histopathological and ultrastructural findings to other segregation-confirmed cases, although none had “classical” centronuclear
myopathy features. The segregation-inconclusive case muscle biopsies had similar histopathological features to those in segregation-confirmed cases.
When no slides were available for review and no EM had been performed, descriptions of both moth-eaten fibers or central lucencies suggestive of
cores on oxidative enzyme stains were recorded as cores.
a
Similar major features in both biopsies.
b
Fulfils histopathological diagnostic criteria for CFTD (fiber size variation 1 type 1 fibers at least 12% smaller than type 2 fibers 1 type 1 fiber predominance 1 no additional structural abnormalities; Clarke and North31). In this particular case, type 1 fibers were 32% smaller than type 2.
c
IN pattern consistent with or reported to be consistent with CNM.
d
Summary of major features in both biopsies from same patient, combined.
e
38/40 5 38 weeks gestation.
f
Previously published case (Ceyhan-Birsoy et al22).
ACh 5 Amanda Charlton (coauthor); B 5 biceps; Bx 5 biopsy; CC 5 centrally placed cores; CFTD 5 congenital fiber type disproportion;
CNM 5 centronuclear myopathy; D 5 deltoid; EM 5 electron microscopy; EO 5 Emily Oates (coauthor); FSV 5 significant fiber size variation;
G 5 gastrocnemius; IN 5 internalized nuclei (considered abnormal if present in 3% fibers); LM 5 light microscopy; MMC 5 multiminicores;
PS 5 paraspinal; Q 5 quadriceps; RP 5 Rahul Phadke (coauthor); S1 5 oldest of 2 affected siblings; S2 5 youngest of 2 affected siblings;
SB 5 Susan Brammah (coauthor); T 5 triceps; TA 5 tibialis anterior; U 5 site unknown.

in 6 of the 7 cases. The absence of predicted truncated
proteins in samples with nonsense and frameshifting
mutations may be due to nonsense-mediated decay, or
protein degradation eliminating the N- and C-termini.
However, western blots with antibodies raised to either
titin’s I-band (9D10) or A-band (MIR) regions did not
detect truncated titin proteins (data not shown). An
exception is the sample from Family 13 (with 2 splice
site changes, 1 of which is predicted to result in in-frame
exon skipping), which contained an additional band that
was Z1Z2-positive but M8M9-negative (see Fig 4, asterisk). This might represent a truncated protein derived
from the mutant TTN allele that is predicted to produce
a truncated 1.5MDa protein. Several other samples
contained barely detectable Z1Z2-positive M8M9-negative bands (see Fig 4, 1 symbols) that are not the size of
predicted truncation proteins. These might represent
mutant titin degradation and/or alternatively spliced
products. The reduced band intensity may be due to
lower levels of protein production and/or the loss of
smaller degradation/splicing products that were not
retained on the gels.
Splice Site Mutation Analysis
A minigene splicing assay showed that the exon 220
c.40558G>C exonic splice site mutation shared by Families 4 and 13 results in in-frame exon skipping, and that
the Family 13 exon 244 c.44816-1G>A mutation results
in frameshift.22
cDNA analysis showed that the Family 6 paternally
inherited extended splice site deletion resulted in inJune 2018

frame skipping of exon 317. No other sample from 70
patients with neuromuscular disease or 184 GTEx
(http://gtexportal.org/home/) control adult skeletal muscle samples showed skipping of this exon.

Discussion
Since MPS “opened the door” to the comprehensive
genetic analysis of TTN, congenital titinopathy has
emerged as an important cause of early onset myopathy.
Using MPS, we identified an international cohort of 30
individuals with early onset muscle weakness and/or contractures, and recessively inherited nonsense, frameshift,
and/or splice site TTN mutations. The clinical features,
muscle histopathology, autopsy, and imaging results of
cohort members were analyzed to identify features with
clinical and/or diagnostic utility.
One of the most striking findings was the degree of
axial involvement, which was present in all patients, manifesting as one or more of the following features: neck
weakness, early onset progressive scoliosis, chest wall
deformities and early onset respiratory insufficiency. Axial
complications, including scoliosis and respiratory impairment, typically progressed rapidly, whereas limb weakness
was often stable or only slowly progressive, and insufficient to prevent acquisition of independent walking in the
majority of patients. This truncal-predominant phenotype
is reminiscent of SEPN1- and severe nemaline myopathy,
and COL6-, LAMA2- and LMNA-congenital muscular
dystrophy.32,33 Congenital contractures were also common, affected distal as well as proximal joints, and often
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involved two or more areas of the body, leading to the
diagnosis of AMC. Acquired limb contractures were common, as was joint hypermobility, features shared with
COL6-myopathy.33
Respiratory complications were the most common
cause of death. Progressive respiratory insufficiency

typically developed within the first 12 years of life, often
necessitating assisted ventilation. With 1 exception, respiratory insufficiency occurred in patients with concomitant
spinal and/or chest wall deformities. Many patients with
significant respiratory impairment remained ambulant, a

FIGURE 3.
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feature also shared with early onset SEPN1-, NEB-, TPM3ACTA1-myopathy and COL6-muscular dystrophy.32
Almost 50% of patients had congenital or early
onset cardiac abnormalities. Cardiomyopathy is sometimes associated with muscle disorders caused by
MYH7, LMNA, FKRP, FKTN, SPEG, ACTA1 and TAZ
mutations32–35; however, it is not typically associated
with other forms of early onset muscle disease. Congenital cardiac defects and a history of dilated cardiomyopathy in heterozygous relatives are not typical features of
other congenital myopathies. Congenital titinopathy
should be considered in the differential diagnosis of
patients with any of these cardiac/family history
features.
It has recently been shown that heterozygous TTN
truncating and essential splice site mutations that alter
both N2BA and N2B, the 2 longest and most abundant
adult cardiac isoforms, increase the risk of adult onset
DCM.15 Truncating mutations that alter fetal and/or the
smaller novex cardiac isoforms, or that impact only the
N2BA isoform (N2BA-only mutations) are not associated
with DCM in the heterozygous state.16 This is presumably because the predominant adult cardiac isoform
(N2B) can still be transcribed from the truncating allele.
Missense variation in TTN is common, and although
some individual variants cause cardiomyopathy, it is not
currently possible to interpret the DCM risk associated
with the vast majority of these variants.
Our data suggest that congenital titinopathy
patients with 2 mutations predicted to impact both
N2BA and N2B cardiac isoforms (N2BA/N2B

mutations) are significantly more likely to have cardiac
involvement than those with other combinations of
mutations. With the available cohort and previously published cases, there was insufficient power to determine
whether patients carrying 1 N2BA/N2B mutation are at
higher cardiac risk than those with biallelic N2BA-only
mutations (ie, 2 mutations that alter N2BA but spare
N2B), as would be expected by extrapolating from the
TTN DCM literature. There were also insufficient data
to confirm whether the pattern of familial risk is highest
for relatives with N2BA/N2B mutations, although both
families with a maternal family history of DCM had a
maternal N2BA/N2B mutation.
If it is confirmed that having biallelic N2BA/N2B
mutations confers the highest risk of cardiac involvement
in congenital titinopathy, this might explain why the
cohort members with 1 metatranscript-only mutation (all
of which spare N2BA and N2B) had fewer cardiac
abnormalities than other patients (only 1/10 had a cardiac anomaly: mild pulmonary stenosis).
Until the cardiac risk factors associated with this
disorder are better understood, and the association
between risk and cardiac isoform involvement is confirmed, cardiac screening is strongly recommended for all
congenital titinopathy patients, and should be considered
in heterozygous carrier relatives, particularly those carrying truncating or splice-altering variants in cardiac constitutive exons.
In combination, the muscle biopsy results of this
study confirm that congenital titinopathy is a pathological “chameleon,” presenting with a wide range of

FIGURE 3: Examples of histopathological and ultrastructural features. All brightfield scale bars 5 50 mm unless otherwise stated.
(A) Centralized nuclei in the pattern of centronuclear myopathy in a hematoxylin and eosin (H&E)-stained quadriceps section
from the Family 3 female proband at age 5 years. Scale bar 5 20 mm. (B) Both internalized and centralized nuclei in an H&Estained quadriceps section from the male proband from Family 5, at age 14 years. One fiber (arrow) has multiple internalized
nuclei, a feature that was much more prominent in biopsies from older patients. This image also shows a very mild increase in
endomysial connective tissue. (C) Electron micrograph (EM) image showing internalized nuclei and scattered, small, poorly
defined areas of sarcomeric disruption consistent with minicores (Sibling 1/Family 1, quadriceps, age 5 14 years, scale
bar 5 20 mm). (D) Lucent areas compatible with multiminicores in a succinate dehydrogenase–stained section from the same
biopsy as shown in C. The multiminicores in D were confirmed ultrastructurally, as shown in F, which presents 2 minicores in a
longitudinally orientated fiber (scale bar 5 5 mm). (E) Multiminicores as discrete nonstaining foci in a longitudinally orientated
paraffin section stained immunohistochemically for desmin (Sibling 2/Family 1, quadriceps, age 5 10 years). (G) EM image of a
myofiber containing a large centrally placed unstructured core with prominent Z-band streaming (star; Sibling 1/Family 1,
quadriceps, age 5 14 years, scale bar 5 10 mm). (H) Significant fiber size variation in the antemortem quadriceps biopsy taken
on day 1, from the male Family 6 proband who died later the same day (scale bar 5 20 mm). (I) Classical features of congenital
fiber type disproportion, including T1 fibers which are > 25% smaller than T2 fibers, and T1 predominance, in the absence of
other abnormalities (adenosine triphosphatase pH 4.3 section from Family 2 proband, site unknown, age 5 3 years). (J) Multiple
cap-like regions (one shown with arrow) in a periodic acid Schiff–stained paraffin section (Sibling 2/Family 1, quadriceps,
age 5 10 years, scale bar 5 20 mm). (K) EM image of a sharply demarcated cap-like region (star) characterized by marked myofibrillar disruption, loss of thick filaments, and thickened Z-discs. The fiber also contains a minicore (arrow) and numerous peripheral mitochondria (Sibling 2/Family 1, quadriceps, age 5 10 years, scale bar 5 10 mm). (L) An area of fibrosis from patient shown
in C (H&E, scale bar 5 20 mm). (M) Schematic representation of the overlap between the main histopathological patterns seen
in patient biopsies. “Other” refers to rarer structural abnormalities: cap-like regions, ring, coiled, and whorled fibers, and central and peripheral mitochondrial accumulations. Black circles indicate patients with two N2A mutations. White circles indicate
patients with 1 N2A mutation and 1 metatranscript-only mutation.
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TABLE 3. Summary of autopsy findings
Family

Cause of Death and Data Source

Autopsy Findings

6

Died on day 1 of life (38/40a)
due to worsening respiratory
distress and poor prognosis.
Complete autopsy report and
review of LM/EM by ACh & SB.

External: Small for gestational age (weight < 3rd percentile), small
placenta, normal fetal/placental ratio, myopathic and dysmorphic
facial features, multiple bilateral upper limb contractures (shoulders, elbows, wrists, fingers), reduced palmar creases, bilateral talipes
equinovarus, congenital femoral and humeral fractures, thin ribs,
undescended testes. Internal (macroscopic and microscopic):
Normal brain, spinal cord and heart; pulmonary hypoplasia (lung:body weight ratio 5 0.6%; < 1.2% indicates hypoplasia).

10

Died at age 13 yr from pneumonia.
Autopsy description
(original in Danish).

External: Height and weight < 3rd percentile, retrognathia, muscle
wasting, limb contractures (elbows, knees), evidence of previous
scoliosis surgery, asymmetrical rib positioning, PEG tube in situ.
Internal (macroscopic and microscopic): No brain or spinal cord
abnormalities, nerve normal; pneumonia, left lower lobe compressed by scoliosis, dilated hypertrophic right ventricle.

a

38 weeks gestation.
ACh 5 Amanda Charlton (coauthor); EM 5 electron microscopy; LM 5 light microscopy; PEG 5 percutaneous endoscopic gastrostomy tube;
SB 5 Susan Brammah (coauthor).

structural abnormalities. Central/internalized nuclei and
cores have been reported in other congenital titinopathy
cases21–23; however, a typical congenital fiber type disproportion muscle picture, cap-like regions, rods, ring,
whorled, and coiled fibers, and central and

circumferential peripheral mitochondrial accumulations
have not been reported previously. Overall, fiber size variation, cores, and internalized nuclei, either alone, or in
combination, were the most common histopathological
abnormalities.

TABLE 4. Cardiac Isoform Analysis
Cardiac
Involvement
Isoform

Fisher’s Exact Test

Yes

No

p

OR (95% CI)

6

2

0.087

6.01 (0.78–78.21)

6

13

10

2

0.009

10.66 (1.59–129.40)

6

14

12

2

0.002

12.75 (1.97–152.30)

6

14

Clinical analysis cohort members only
2 N2BA/N2Ba
b

Other

21,23,24

Cohort 1 published families with 2 truncating muts
2 N2BA/N2Ba
Otherb

21,23,24

Cohort 1 published families with 2 truncating muts
1 truncating & 1 missense mut23
2 N2BA/N2Ba
b

Other

or

Table shows the 2 3 2 Fisher’s Exact Test tables used to analyze the association between carriage of 2 mutations (in trans) that impact both N2BA
and N2B cardiac isoforms, and the presence of cardiac pathology in one or more affected family members.
a
Patients with 2 mutations predicted to alter both N2BA and N2B cardiac isoforms (see Supplementary Table 1).
b
Patients with other combinations of mutations.
CI 5 confidence interval; mut 5 mutation; OR 5 odds ratio.
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FIGURE 4: Western blot analysis of patient muscle samples. Antititin antibodies were used that were specific for the titin Nterminus (Z1Z2; top panel) or C-terminus (M8M9; bottom panel). The 4 left lanes are controls, and the 7 right lanes are biopsies from patients (from Families 4, 5, 13, 15, and 16), or segregation-inconclusive cases (Families 28 and 29). All patients have
mutations in both of their TTN alleles that produce proteins that are predicted to vary in size. The segregation-inconclusive
cases also have 2 TTN mutations that are predicted to produce proteins of different sizes if their mutations are (as suspected)
in trans. The bottom of the figure shows the expected protein mass, assuming that the wild-type full-length titin is 3.8MDa
and that the mutant protein is reduced by the size of the missing exons(s). The largest predicted proteins are in patient biopsies from Families 28, 29, 4, 13, and 16 at nearly full size (in-frame deletion of a single small exon near the middle of titin),
consistent with their observed expression of a large titin that reacts with both Z1Z2 and M8M9. The largest predicted proteins
in the remaining 2 patients (from Families 5 and 15) are slightly smaller than full-length titin. The patient from Family 5 has a
TTN truncating mutation in exon 359 reducing its size by 112KDa and eliminating the M8M9 binding site, consistent with the
finding that titin in muscle from this patient reacts with Z1Z2 but not M8M9. The patient from Family 15 has a frameshift
mutation in exon 364. Although this leaves the binding site for M8M9 intact, Patient 15 titin reacts only weakly with M8M9 (in
contrast with the strong Z1Z2 reactivity), suggesting that the antigen availability is reduced, or perhaps that the mutant titin is
degraded near its C-terminus. The second mutant allele is, in all of the patients/cases, predicted to produce a protein that is
between 1.5 and 2.7MDa (see bottom of figure) that reacts with Z1Z2 but not M8M9. Although weak bands with the expected
reactivity are present in some of the patients, they are very minor relative to (nearly) full-length titin, except for the band
marked by an asterisk in the biopsy from Family 13. Also note that several patients have a Z1Z2-positive, M8M9-negative
band at a molecular mass of 1.0MDa. However, this band is also seen in several control samples and is present at the same
size in different patients with different mutations and therefore it is unlikely that this 1.0MDa band is mutation-specific.
LV 5 left ventricle; T2 5 degradation product of titin that mainly consists of titin’s A-band segment; Vast Lat 5 Vastus lateralis.

Muscle from congenital titinopathy patients sometimes showed a typical CNM pattern. The absence of
ophthalmoplegia may be helpful in discriminating
between congenital titinopathy and other CNM genetic
subtypes.
June 2018

A subset of muscle biopsies had a dystrophic appearance,
sometimes in association with elevated CK, suggesting histopathological overlap with congenital muscular dystrophies.
Congenital titinopathy is also an important diagnosis to consider in genetically unresolved core and cap myopathy cases.
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Ten patients from 8 families had 1 mutation that spares
the N2A skeletal muscle isoform: a metatranscript-only
mutation. These mutations were within 1 of 4 exons (163,
172, 181, and 201) included within the I-region PEVK segment of the established complete TTN metatranscript. In
further support of the pathogenicity of these mutations, 1 of
these mutations (exon 163: c.35794G>T; p.Glu11932*)
was shared by 5 unrelated cohort families and 1 segregationinconclusive case. The utility of a subgroup analysis of clinical features associated with patients carrying 1
metatranscript-only mutation was limited given the small
subgroup size; however, the clinical features were largely similar to other cohort members. Furthermore, FernandezMarmiesse et al recently described an AMC case with typical
congenital titinopathy clinical and histopathological features
(without cardiac involvement), and a homozygous truncating
mutation within an additional metatranscript-only exon.24
Together, these findings suggest that the metatranscript-only
mutations identified in our cohort patients are “true” congenital titinopathy-causing mutations.
Titin developmental isoforms have been characterized in multiple species, including humans, mice, and
rabbits.9,10 They are longer than their mature muscle
counterparts, due to an elongated I-band PEVK spring
segment that includes exons absent from mature isoform
transcripts. Human fetal skeletal muscle isoforms have
not been formally characterized; however, 3 of the 4
metatranscript-only PEVK exons (163, 172, and 181)
were originally detected in a human fetal skeletal muscle
cDNA expression library,36 and 3 (163, 172, and 201)
have been detected in mouse fetal skeletal muscle.10
Overall, these findings suggest that the pathogenesis of
congenital titinopathy can result from mutations in exons
that are present in one or more developmental
isoform(s).
All muscle samples analyzed by western blot
showed full-length or nearly full-length titin. This finding raises the possibility that the presence of a near-normal sized protein might be essential to survival. This is
supported by mouse studies that show that Ttn-deficient
mice are embryonic lethal due to abnormal cardiac morphogenesis and dysfunction.37,38
Interestingly, all families had at least 1 mutation
predicted to result in production of a near-normal sized
titin. Most had at least 1 C-terminal M-line exon mutation, or at least 1 splice site mutation predicted or shown
to cause in-frame loss of a single exon, which should
result in a near-normal protein product. All remaining
patients had 1 metatranscript-only mutation whose
impact is unknown but might not affect transcript length
or protein size in mature muscle. Some natural readthrough of nonsense mutations might also be responsible
1122

for minor amounts of full-length protein seen on western
blot. Protein analysis of muscle from additional patients
will shed further light on whether the presence of a full,
or near full-length protein band is a consistent finding in
patients who do not succumb to the disorder during
development.
Congenital titinopathy increasingly appears an important, common, and potentially severe form of axialpredominant congenital myopathy. Analysis of the clinical,
histopathological, imaging, and autopsy features of this 30member truncating/splice mutation cohort significantly
expands our understanding of the clinical features and natural history of this disorder. This study will facilitate the diagnosis and management of affected individuals, inform
cardiac surveillance in heterozygous relatives, and guide clinical decision making around severely affected infants. In
addition, the unexpected discovery of metatranscript-only
mutations in a significant subset of patients suggests that
yet-to-be-characterized developmental skeletal muscle isoform(s) are involved in the pathogenesis of this disorder.
Studies are currently underway to further improve cardiac
risk prediction, gain a molecular-level understanding of
disease-associated mutations at the RNA and protein levels,
and extend our understanding of the pathological mechanisms involved in this emerging disorder.
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